Multiple Myeloma Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
11506A Collection of Bone Marrow Samples from Patients with Multiple Myeloma who Already are Undergoing a Bone Marrow Biopsy and Aspirate
10-064-B Molecular characterization of hematopoietic malignancies
11-0445 A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles
Select
IRB12-1466 A Phase 3, Randomized, Controlled, Open- label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Select
IRB12-1218 A Phase I/IIa multi-dose escalation study of BT062 in combination with Lenalidomide and Dexamethasone in subjects with relapsed or relapsed/refractory Multiple Myeloma
Select
IRB12-1088 Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma
Select
12-1725 Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment with Carfilzomib, Lenalidomide and Low dose Dexamethasone (CRd) in Transplant Candidates with Newly Diagnosed, Multiple Myeloma (MM) Requiring Systemic Chemotherapy
Select
IRB14-0033 A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Select
IRB14-0042 Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Combination With Lenalidomide or Oral Cyclophosphamide in Patients with Newly Diagnosed Multiple Myeloma
Select
IRB14-0624 A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0711 A Phase I, Multicenter, Open-Label, Dose-Escalation Combination Study Of Pomalidomide, Marizomib, And Low-Dose Dexamethasone (PMD) In Subjects With Relapsed Or Refractory Multiple Myeloma.
Select
IRB14-0899 Phase II Randomized Trial of Continuation of Post-Transplant Maintenance with Single-Agent Lenalidomide vs. Consolidation/Maintenance with Ixazomib-Lenalidomide-Dexamethasone in Patients with Residual Myeloma
Select
IRB14-0364 Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed or Refractory Multiple Myeloma
IRB14-1265 Phase 1b Study Of Carfilzomib Administered Once Weekly In Combination With Lenalidomide And Dexamethasone In Subjects With Multiple Myeloma
Select
IRB14-1266 A Phase 3, Randomized, Controlled, Open-label Study of VELCADE® (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy.
Select
IRB14-1076 Phase I Study of an Oncofetal Antigen (“OFA”) Multi-Peptide Immunotherapy (“BB-MPI-03”) in Subjects with Hematologic Cancer

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team